FDA considers revoking approval of Avastin for advanced breast cancer. by Rob Stein, Washington Post, Monday, August 16, 2010
Avastin® (manufactured by Roche, Genentech) makes the news again as the federal government considers the recommendation of a review committee to revoke the approval of Avastin for treating advanced breast cancer.
Questions are rife. Is this a sampling of the government’s trying to control costs, possibly at the expense of the patient? Is it ethically correct to revoke approval when some patients are experiencing success with the drug even though the statistics support a different story? Conceivably, if the FDA revokes approval, insurance companies will probably stop supporting payment for this treatment.
5 6 7 8
© 2004-2010 Donna Peach. All rights reserved.